|
Plant name | Isolated compound | Test model | Dose | Route | Mechanism of hepatoprotective action | Ref. |
|
A. vera | Polysaccharides | Alcohol-induced liver diseases in mice | 10 mg/kg | IP | Reduced liver biomarkers via increasing lipolysis through upregulating hepatic expression of lipolytic genes AMPK-α2 and PPARα, as well as reduced hepatic inflammation via downregulation of TLR-4 and MyD88 with upregulation of IκB-α | [236] |
Aloe emodin | Myofibroblastic differentiation study in rat hepatic stellate cells | 0.004–0.04 μM/mL | Cell culture | Inhibition of stellate cell proliferation by reduced DNA synthesis and inhibition of type I collagen production and smooth muscle alpha-actin expression | [221] |
CCl4-induced hepatic injury in rats | 185 μM/kg | IP | Reduced hepatocyte death and inflammation through inhibition of TNF-α and LPO | [220] |
Aloin | Alcohol-induced liver injury in mice | 24 and 72 μM/kg | Oral | Attenuated lipid accumulation via inhibition of SREBP-1c regulate gene, as well as reduced hepatic inflammation through downregulation of TLR-4 and TNF-α | [223] |
TAA-induced hepatic retinopathy | 120 and 240 μM/kg | Oral | Suppressed retinal injury associated with liver toxicity through the normalization of Kir4.1 and aquaporin-4 channels | [224] |
|
A. spinosus | Rutin | CCl4-induced hepatic damage in rats | NA | Oral | ↓ the elevated level of transaminases, phosphatases, total protein, albumin and LPO as well as ↑ upregulation of antioxidant enzymes | [157] |
|
A. paniculata | Andrographolide | EtOH-induced liver toxicity in mice | 177–1427 μM/kg | IP | Restored the elevated serum level of GOT, GPT, ACP, ALP, and LP | [175] |
Nonalcoholic high-fat-diet-induced fatty liver disease in rat | 143 μM/kg | Oral | Restored the elevated level of serum ALT, AST, and ALP, as well as normalized the hepatic architecture | [183] |
Palmitate-oleate-induced steatotic in HepG2 cells | 12.5–50 μM | Cell culture | Ameliorated hepatic steatosis and lipotoxicity via reduced lipid accumulation |
APAP-induced liver damage in rat | 2–34 μM/kg | Oral | Increased viability of hepatocytes and ↓ the elevated SGOT, SGPT, and ALP in serum and isolated rat hepatocytes | [176] |
CCl4 and tert-butylhydroperoxide (t-BHP) intoxicated mice | 286 μM/kg | IP | ↓ the elevatedMDA, SGPT, and ALP and ↑ liver GSH activity | [177] |
CCl4-induced liver toxicity in male mice | 286 μM/kg | IP | ↓ the elevated SGPT, SGOP, ALP, TB, and TG, as well as protected drug-metabolizing enzyme | [178] |
Arabinogalactan proteins | EtOH-induced liver toxicity in mice | 62–500 mg/kg | IP | Restored the elevated serum level of GOT, GPT, ACP, ALP, and LP | [175] |
Isoandrographolide | Nonalcoholic high-fat-diet-induced fatty liver disease in rat | 143 μM/kg | Oral | Restored the elevated level of serum ALT, AST, and ALP, as well as normalized the hepatic architecture | [183] |
Palmitate-oleate-induced steatotic in HepG2 cells | 12.5–50 μM | Cell culture | Reduced lipid accumulation and leakage of LDH and transaminases (ALT and AST) |
3,19-Acetonylidene andrographolide | Nonalcoholic high-fat-diet-induced fatty liver disease in rat | 128 μM/kg | Oral | Restored the elevated level of serum ALT, AST, and ALP, as well as normalized the hepatic architecture |
Palmitate-oleate-induced steatotic in HepG2 cells | 12.5–50 μM | Cell culture | Ameliorated hepatic steatosis and lipotoxicity via reduced lipid accumulation |
Andrographiside | CCl4 and t-BHP intoxicated mice | 195 μM/kg | IP | ↓ the elevated MDA, SGPT, and ALP and ↑ liver GSH activity | [177] |
Neoandrographolide | CCl4 and t-BHP intoxicated mice | 208 μM/kg | IP | ↓ the elevated MDA, SGPT, and ALP and ↑ liver GSH activity |
|
B. orellana | Bixin | High-fat-diet-induced obese mice | 127 μM/kg | Oral | ↓ all metabolic parameters including body weight, Lee’s index, adiposity, CHT, TG, CHT/HDL-c, glucose, AST, and ALT | [234] |
|
C. cajan | 43 kD protein | TAA-induced liver toxicity in mice | 2 mg/kg | IP | ↓ the elevated SGPT, ALP, and LPO, as well as ↑ liver enzymes SOD, CAT, and GST | [295] |
|
C. tinctorius | Kaempferol 3-O-rutinoside and kaempferol 3-O-glucoside | CCl4-induced oxidative liver injury in mice | 336 and 672 μM/kg | Oral | ↓ the elevated AST, ALP, and MDA and ↑ liver enzyme GSH, SOD, and CAT, as well as normailized hepatocyte architecture | [158] |
|
C. fistula | Catechin | STZ-induced hepatic injury in diabetic rats | 69 μM/kg | Oral | ↓ the elevated AST, ALT, ALP, LDL, HDL, TC, and TG and normalized hepatic and renal cell damage | [159] |
|
C. longa | Curcumin | HgCl2-induced liver toxicity in rats | 217 μM/kg | Oral | ↓ the elevated ALP, LDH, TB, γ-GT, MDA, and TG, as well as ↑ the protective effect on drug-metabolizing CYP 2E1 enzymes | [123] |
Lindane-induced oxidative stress in male rats | 272 and 544 μM/kg | Oral | Decreases LPO and ↑ liver antioxidant enzyme SOD, GSH, CAT, GST), GPx, GR and NADPH quinine reductase (QR) | [203] |
Dimethylnitrosamine- (DMN-) induced liver cirrhosis in rats | 272 μM/kg | Oral | Restored the electrical conductivity and ↓ the elevated AST and ALT, as well as attenuated fibrosis and inflammatory response | [209] |
CCl4-induced hepatotoxicity in rats and mice | 136 and 272 μM/kg | Oral | ↓ the elevated AST, ALT, ALP, and MDA and ↑ liver enzyme GSH and CAT, as well as normalized hepatic inflammatory lessions | [201] |
APAP-induced liver damage in mice | 544 μM/kg | Oral | ↓ the elevated ALT, AST, and LPO, as well as ↑ liver enzyme SOD, CAT, and GPx | [202] |
Alfatoxin B1 (AFB1)-induced hepatotoxicity in rats | 544 μM/kg | Oral | ↓ the elevated liver marker enzymes and LPO and ↑ liver enzyme GSH, SOD, CAT, and GPx | [205] |
AFB1-induced hepatotoxicity in rats | 0.05% w/w with diet | Oral | Modulated drug-metabolizing enzyme and ↓ AFB(1)-N(7)-guanine adduct excretion in the urine, DNA adduct in the liver, and albumin adduct in the serum | [204] |
TAA-induced hepatic fibrosis in mice | 814 μM/kg | Oral | Inhibiting HSC activation and inflammatory responses and inducing apoptosis of damaged hepatocytes via upregulating p53 protein expression and downregulating Bcl-2 mRNA expression | [214] |
Hepatitis B (HBV)-transfection HepG2215 cell line | 50–150 µM | Cell culture | Inhibits HBV gene expression and DNA replication via downregulation of PGC-1α | [217] |
Sesquiterpene fraction: ar-turmerone, α-tumerone, and β-tumerone | D-galactosamine-induced liver injury in rats | 0.5% w/w with diet | Oral | Suppressed the elevated LDB, ALT, and AST levels | [218] |
|
E. ribes | Embelin | CCl4-induced peroxidative liver damage in rats | 85 µM/kg | Oral | Upregulatioon of liver antioxidant and cytochorme P450 enzymes, as well as ↓ the elevated AST, ALT, ALP, γ-GT, LPO, and LDH | [228] |
DENA-/PB-induced hepatocarcinogenesis in rats | 170 µM/kg | Oral | ↓ hepatic hyper plastic nodules, body weight loss, and hepatic diagnostic markers | [226] |
DENA/PB-induced hepatocarcinogenesis in rats | 170 µM/kg | Oral | Upregulated the hepatic glutathione antioxidant defense, ↓ LPO, and minimized the histological alterations | [227] |
CCl4-induced liver toxicity in rats | 170 and 240 µM/kg | Oral | ↓ the elevated SGPT, SGOT, ALP, γ-GT, GST, and lipid peroxidase, as well as ↑ liver glutathione and reduced cellular inflammation | [296] |
|
I. tinctora | trans-Tetracos-15-enoic acid (TCA) | CCl4- and APAP-induced hepatotoxicity in rats and mice | 34–273 µM/kg | Oral | Accelerated regeneration of parenchymal cells and ↓ membrane fragility, LPO, and leakage of marker enzymes, as well as ↑ liver GSH | [232] |
|
L. inermis | Gallic acid | CCl4-induced hepatotoxicity in rats | 294 µM/kg | IP | ↓ the elevated ALT, AST, ALP, LDH, and ROS, as well as ↑ liver SOD, CAT, and GPx and normalized hepatocellular architecture | [170] |
|
M. charantea | Cucurbitane-type triterpene glycosides | Antihepatic fibrosis activity against murine hepatic stellate cells (t-HSC/Cl-6) and antihepatoma activity in HepG2 and Hep3B cells | Upto 100 µM | Cell culture | Inhibition the activation of t-HSC/Cl-6 cells and ↓ cytotoxicity of Hep3B and HepG2 cells | [197] |
Norcucurbitane-type triterpenoids | t-BHP-induced injury on HepG2 cells | 5–10 µM | Cell culture | ↑ the viability of HepG2 cells | [198] |
|
O. basilicum | Triterpene acid: betulinic, oleanolic, ursolic, alphitolic, 3-epimaslinic, and euscaphic acids | Iron ascorbate-stimulated lipid peroxidation in liver homogenate | 0.1–5 mg/mL | Cell culture | ↓ liver oxidative stress by inhibition of LPO | [187] |
|
P. olerace | Portulene diterpene, lupeol, b-sitosterol, and daucosterol | CCl4-induced hepatic toxicity in rats | 10–50 mg/kg | Oral | ↓ the elevated level of SGOT, SGPT, and TB | [184] |
|
S. jambos | Flavonoid fraction: myricetin, ellagic acid rahmnoside, quercetin 3-O-xylosyl-(1 ⟶ 2), rhamnoside, and rosmarinic acid | CCl4-induced liver toxicity in rats | 200 mg/kg | Oral | ↓ the elevated liver markers ALT, AST, TB, TC, TG, and MDA, as well as ↑ liver enzyme GSH and SOD | [167] |
Sodium arsenite-induced oxidative stress in HepG2 hepatocytes | 50 µgmL | Cell culture | ↓ the ROS production via inhibition of p38 and its target MAPKAPK-2-activated signaling cascade |
|
T. purpurea | Flavonoid fraction: Coumarins, flavonoids, flavanones, and quercetin | CCl4-induced hepatotoxicity | 100 mg/kg | Oral | ↓ the elevated liver markers SGOT, SGPT, ALP, and bilirubin | [162] |
|
T. chebula | Chebulic acid | t-BHP-induced oxidative stress in isolated rat hepatocytes | 280 µM/mL | Cell culture | ↓ the ROS and cell cytotoxicity and the ratio of GSSH with GSH | [172] |
t-BHP-induced oxidative stress in HepG2 cells | 0.4, 2, and 10 µM | Cell culture | ↓ the oxidative stress through controlling the activation of Nrf2 and its cytoprotective enzymes HO-1 and γ-GCL | [173] |
|